Drugs /

anti-thymocyte globulin

Back to Drugs List

Overview

NCI Definition [1]:
A purified gamma immunoglobulin (IgG) with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.

Clinical Trials

View Clinical Trials for anti-thymocyte globulin

Anti-thymocyte globulin has been investigated in 18 clinical trials, of which 12 are open and 6 are closed. Of the trials investigating anti-thymocyte globulin, 3 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), 2 are phase 3 (1 open), and 1 is no phase specified (0 open).

Complex karyotype, Very Complex karyotype, and BCR-ABL1 Fusion are the most frequent biomarker inclusion criteria for anti-thymocyte globulin clinical trials.

Acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes are the most common diseases being investigated in anti-thymocyte globulin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Anti-Thymocyte Globulin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Anti-Thymocyte Globulin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating anti-thymocyte globulin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
lymphocyte immune globulin, globulins, antithymocyte, atg, globulin, anti-thymocyte, lymphocyte immune globulin, antithymocyte globulin, antithymocyte globulins, globulin,anti-thymocyte, globulins, anti-thymocyte, lymphocyte immunoglobulin (substance), antithymoglobulin, atgam, anti-thymocyte globulin, anti-thymocyte globulin, antithymocyte serum, thymoglobulin, ats, anti thymocyte globulin, lymphocyte immune globulin, anti-thymocyte globulin, globulin, antithymocyte, lymphocyte immunoglobulin, anti-thymocyte globulin, lymphocyte immune globulin, anti thymocyte globulin, thymoglobulin, antithymocyte globulin, anti-thymocyte globulins, antithymoglobulins
Drug Target(s) [2]:
THY1
NCIT ID [1]:
C278
SNOMED ID [1]:
F-C8001

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.